Leaving MSDLink.ie
You are about to exit this MSD Ireland website. MSD Ireland makes no warranties or representations of any kind as to the accuracy, completeness, reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information. Inclusion of any third party link does not imply an endorsement or recommendation by MSD Ireland.
This site is intended for health care professionals of Ireland.
Copyright © 2009-2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
tcm:4475-69797-4 NuvaRing /products/nuvaring/ sameWindow Primary tcm:4475-496308-64 010_About NuvaRing about.xhtml tcm:4475-496309-64 020_Patient Profile patient-profile.xhtml tcm:4475-496311-64 030_Patient Preference who-mec-guidelines.xhtml tcm:4475-496313-64 040_Efficacy efficacy.xhtml tcm:4475-496310-64 050_Vaginal Delivery vaginal-delivery.xhtml tcm:4475-496312-64 060_Steady Hormone Release steady-hormone-release.xhtml tcm:4475-496314-64 070_Convenience convenience.xhtml tcm:4475-496315-64 080_Predictable Bleeding Pattern predictablep-bleeding-patternt.xhtml tcm:4475-496317-64 100_Summary summary.xhtml tcm:4475-535898-64 110_Patient Benefits patient-benefits.xhtml tcm:4475-496318-64 120_Professional Resources professional-resources.xhtml tcm:4475-496319-64 122_-Support Materials support-materials.xhtml tcm:4475-496320-64 124_-Visuals and Videos visuals-videos.xhtml tcm:4475-496321-64 126_-Slide Sets slide-sets.xhtml tcm:4475-496323-64 130_Patient Resources patient-resources.xhtml tcm:4475-496324-64 132_-Patient Information patient-information.xhtml tcm:4475-496325-64 134_-Support Materials Resources support-materials-resources.xhtml tcm:4475-515989-64 140_Abridged Prescribing Information abridged-prescribing-information.xhtml tcm:4475-496328-64 LeftNav_NuvaRing leftnav.xml tcm:4475-496498-64 Study Designs study-design.xhtml False
tcm:4475-496308-64
tcm:4475-496308-64 010_About NuvaRing about.xhtml
tcm:4475-496308-64 010_About NuvaRing about.xhtml
NUVARING (ethinyloestradiol, etonogestrel)
NUVARING is therapeutically indicated for contraception. NuvaRing is intended for women of fertile age. The safety and efficacy have been established in women aged 18 to 40 years. The decision to prescribe NuvaRing should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with NuvaRing compares with other CHCs.
NuvaRing is a combined hormonal contraceptive in the form of an intra-vaginal ring. It contains both an oestrogen and a progestogen, 11.7 mg etonogestrel (ENG) and 2.7 mg ethinylestradiol (EE). It is inserted into the vagina for 3 weeks by the user herself and then removed by the user for 1 week.
Please consult medicines.ie for further information
SPC: Click here
PIL: Click here